TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03056209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KL1333 25 mg
Description: oral administration, single dose, 25 mg 1 tab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KL1333 50 mg
Description: oral administration, single dose, 25 mg 2 tabs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KL1333 100 mg
Description: oral administration, single dose, 100 mg 1 tab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KL1333 200 mg
Description: oral administration, single dose, 100 mg 2 tabs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KL1333 400 mg
Description: oral administration, single dose, 100 mg 4 tabs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KL1333 600 mg
Description: oral administration, single dose, 100 mg 6 tabs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KL1333 800 mg
Description: oral administration, single dose, 100 mg 8 tabs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral administration, placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral administration, placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral administration, placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral administration, placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral administration, placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral administration, placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral administration, placebo
Study: NCT00751335

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP with ThermoSmart, then CPAP without ThermoSmart
Description: CPAP with ThermoSmart is the application of CPAP with heated humidification and a heated breathing tube.~CPAP without ThermSmart is the application of CPAP with heated humidification without a heated breathing tube.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP without ThermoSmart, then CPAP with ThermoSmart
Description: CPAP with ThermoSmart is the application of CPAP with heated humidification and a heated breathing tube.~CPAP without ThermSmart is the application of CPAP with heated humidification without a heated breathing tube.
Study: NCT02357524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oritavancin
Study: NCT01001884

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: caregiver psychoeducational consultation program (CPCP)
Description: 6-session caregiver psychoeducational consultation program (CPCP)
Study: NCT04763824

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telementoring with Practice Facilitation
Description: We are attempting to provide education and encourage practice change

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telementoring with Practice Facilitation
Description: We are attempting to provide education and encourage practice change
Study: NCT01422395

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Freezing
Description: Vitrification
Study: NCT02743494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study: NCT02552537

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: patients with walnut allergy will be exposed during 5 days before food challenge with Omeprazole

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: patients with walnut allergy will be exposed during 5 days before food challenge with Placebo
Study: NCT02501486

Intervention type: OTHER
Group type: OTHER
Intervention: ACTH stimulation test
Description: An ACTH stimulation test will be done
Study: NCT01871428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aleglitazar
Description: 150 mcg orally daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching aleglitazar placebo orally daily
Study: NCT04352244

Intervention type: PROCEDURE
Intervention: Fat biopsy
Description: The fat biopsy is performed during a scheduled procedure at the Beth Israel Deaconess Medical Center (BIDMC). Routine preoperative procedures will be followed, including local anesthesia (numbing a particular region of the body) or general anesthesia (being put to sleep).~Adipose tissue will be sampled from different depots depending on the procedure. For example, the surgeon will collect adipose tissue from the neck and supraclavicular depots from cervical spine, thyroid, and parathyroid procedures; perinephric fat from adrenalectomies, omental fat from abdominal procedures, and paraspinal fat from lumbar spine procedures. Up to 5 pieces of fat tissue weighing about three to six grams will be removed. All other aspects of the surgical procedure will proceed as planned. Samples will be prepared for subsequent laboratory analysis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: A blood sample will be collected in the fasting state either during preoperative testing or in the preoperative area on the day of planned procedure for measurement of adipose functional markers (leptin, adiponectin) and insulin resistance (insulin, C-peptide), and measures of glycemia (glucose, hemoglobin A1c).

Intervention type: GENETIC
Intervention: Blood sample for DNA analysis
Description: Targeted resequencing of DNA to identify variants associated with adipose phenotypes will be performed.
Study: NCT04313595

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RespirHó
Description: The system is a wearable, unobtrusive inertial-sensor-based device for long-term breathing pattern monitoring, also during daily life activities. It consists of three IMU-sensor units (3-axis accelerometer, 3-axis gyroscope, 3-axis magnetometer), positioned respectively on the patient's abdomen and thorax, and on a body area integral with thorax but not affected by espiratory movements. The peripheral units, placed on thorax and abdomen are used to record orientation changes during respiratory movements. The third unit is a central reference unit (hereafter CRU) that receives data from the other two units, save them on an SD card and communicate via Bluetooth with a smartphone / tablet / PC. Moreover, this unit detects only non-respiratory movement, representing not only a pure source of noise that must be removed from the thoracic and bdominal signals, but also a pure source of additional information regarding the state of ctivity of the subject .
Study: NCT01218477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Oral tablets, 100-140 mg once daily, depending on cohort (100 mg for those with chronic myeloid leukemia \[CML\]-chronic phase; 140 mg for those with CML-advanced phase)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Oral tablets, 100-140 mg once daily, depending on cohort (100 mg for those with chronic myeloid leukemia \[CML\]-chronic phase; 140 mg for those with CML-advanced phase)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Oral tablets, 100-140 mg once daily, depending on cohort (100 mg for those with chronic myeloid leukemia \[CML\]-chronic phase; 140 mg for those with CML-advanced phase)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Oral tablets, 100-140 mg once daily, depending on cohort (100 mg for those with chronic myeloid leukemia \[CML\]-chronic phase; 140 mg for those with CML-advanced phase)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-833923
Description: Oral capsules, 50-200 mg, depending on cohort (100 mg for those with CML-chronic phase; 140 mg for those with CML-advanced phase)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-833923
Description: Oral capsules, 50-200 mg, depending on cohort (100 mg for those with CML-chronic phase; 140 mg for those with CML-advanced phase)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-833923
Description: Oral capsules, 50-200 mg, depending on cohort (100 mg for those with CML-chronic phase; 140 mg for those with CML-advanced phase)
Study: NCT03941327

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: AxoGuard Nerve Cuff
Description: A porcine collagen implant will be used to make a protective sheath around the participant's exposed spinal accessory nerve during surgery. This will be performed by physically wrapping the exposed nerve with the implant and suturing the ends together. The goal is to protect nerve from adhesions and compression in the absence of normal protective lymphatic soft tissue.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AxoGuard Nerve Cuff
Description: A porcine collagen implant will be used to make a protective sheath around the participant's exposed spinal accessory nerve during surgery. This will be performed by physically wrapping the exposed nerve with the implant and suturing the ends together. The goal is to protect nerve from adhesions and compression in the absence of normal protective lymphatic soft tissue.
Study: NCT01017211

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: auricular acupuncture
Description: Experimental group to receive ear needles in the Battlefield Acupuncture points.~Sham group to receive ear needles at points thought to be ineffective but standardized.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: auricular acupuncture
Description: Experimental group to receive ear needles in the Battlefield Acupuncture points.~Sham group to receive ear needles at points thought to be ineffective but standardized.
Study: NCT03761199

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whole body cryostimulation
Description: In this research project will be performed 15 treatments in cryogenic chamber (1 once a day, every day, with a break on Saturdays and Sundays). Cryostimulation will be conducted in a cryochamber located in the Małopolska Cryotherapy Centre in Kraków, Poland (Polish: Małopolskie Centrum Krioterapii). The whole body cryostimulation (WBC) exposure will be administered in a special temperature-controlled unit which consists of two rooms (-60° and -120°C). Throughout the session, the participants will be under direct supervision of qualified doctor.

Intervention type: OTHER
Group type: OTHER
Intervention: whole body cryostimulation
Description: In this research project will be performed 15 treatments in cryogenic chamber (1 once a day, every day, with a break on Saturdays and Sundays). Cryostimulation will be conducted in a cryochamber located in the Małopolska Cryotherapy Centre in Kraków, Poland (Polish: Małopolskie Centrum Krioterapii). The whole body cryostimulation (WBC) exposure will be administered in a special temperature-controlled unit which consists of two rooms (-60° and -120°C). Throughout the session, the participants will be under direct supervision of qualified doctor.
Study: NCT03386409

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Free safe firearm storage device distribution
Description: Participants in the experimental phase of the study receive a safe firearm storage device at the time of study enrollment. They are randomized to receive a free device. Safe firearm storage devices include a California Department of Justice-approved lock box, trigger lock and/or cable lock.
Study: NCT00559572

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational group sessions
Description: Motivational group sessions include 4 weeks of weekly 1-hour exercise information sessions.
Study: NCT03386409

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low cost safe firearm storage device
Description: Participants in the experimental phase of the study receive a safe firearm storage device at the time of study enrollment. They are randomized to receive a low cost ($5) device. Safe firearm storage devices include a California Department of Justice-approved lock box, trigger lock and/or cable lock.
Study: NCT03446417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-e4
Description: Oral dose, tablet, daily dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-e4
Description: Oral dose, tablet, daily dosing
Study: NCT01821456

Intervention type: DRUG
Intervention: Antiinfectives
Description: To analyze to efficacy of (novel) drug therapies
Study: NCT01407796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endotoxin (E. coli O:113, Reference Endotoxin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F](+/-)NOS
Study: NCT02584361

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Round window approach
Description: In this group the insertion of the electrode into cochlea will be performed through an incision in the membrane (paracentesis) of the round window (round window approach = RWA).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cochleostomy
Description: In this group the insertion of the electrode into cochlea will be performed by drilling a hole in cochlea (cochleostomy).
Study: NCT02097342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: Tablet Linagliptin (5mg) per oral, once daily will be given to 10 patients for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet placebo per oral, once daily will be given to 10 patients for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voglibose
Description: Tablet Voglibose (0.2mg) per oral thrice daily(with meals) to 10 patients for 6 months
Study: NCT04066634

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vivio System
Description: The Vivio Analysis Software is an analysis software that assists in identifying suspected systolic murmurs associated with aortic stenosis. The Vivio Analysis Software is used with the Vivio System, a non-invasive device used for the detection and amplification of sounds from the heart and arteries.
Study: NCT04112979

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music
Description: 45 dB SL, normalized, high-frequency sampled W.A. Mozart Symphony n°4 in D K19 and n°5 in B-flat K22 (from Mozart Symphonies Vol. I - Adam Fisher, Dacapo Records, Frederiksberg C., Denmark, 2013)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mother's lap
Description: 45 dB SL, normalized and filtered, high-frequency sampled heartbeat sound, 75 bpm tempo, looped

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Soundproof earplugs
Description: Disposable foam earplugs with a noise attenuation of at least 30 dB
Study: NCT01330654

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metoprolol
Description: 50mg PO BID starting two weeks prior to surgery. Patients will be reevaluated one week prior to surgery. If their pulse is above 70, the dose will be increased to 100mg BID. If the HR is 50-70, the dose will not be changed. If the pulse is below 50, the dose will be decreased to 25mg. This dose will be continued for thirty days after operation.
Study: NCT04454645

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mABC
Description: Intervention targets parenting sensitivity and nurturance.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mDEF
Description: Intervention targets parenting enhancing infant cognitive development
Study: NCT03464916

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR2 Anti-CD38 A2 CAR-T Cells
Description: Autologous IV infusion; dose-escalation
Study: NCT02758301

Intervention type: DEVICE
Intervention: Reveal LINQ™ Insertable Cardiac Monitor (ICM)
Description: Insertable Cardiac Monitor with LINQ™ HF Investigational RAMware download
Study: NCT01793259

Intervention type: DRUG
Group type: OTHER
Intervention: methotrexate prefilled pen

Intervention type: DRUG
Group type: OTHER
Intervention: methotrexate prefilled pen

Intervention type: DRUG
Group type: OTHER
Intervention: methotrexate prefilled syringe

Intervention type: DRUG
Group type: OTHER
Intervention: methotrexate prefilled syringe
Study: NCT02062983

Intervention type: DRUG
Intervention: Herceptin
Description: Herceptin will be administered in different way per each setting as follow::total herceptin cycles are 18.~Neu Adjuvant : chemo+herceptin, Surgery (hold herceptin) , Resume herceptin for 1 year period Adjuvant : Surgery, chemo+herceptin for 1 year period Metastatic : chemo+herceptin until progression.
Study: NCT01522430

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal angiography followed by renal sympathetic denervation
Description: Radiofrequency catheter based therapy for renal denervation: Symplicity catheter will be advanced into the renal artery and connected to a radiofrequency generator. As previously described, four-to-six discrete, low-power radio frequency treatments will be applied along the length of both main renal arteries. At least four radiofrequency applications will be delivered in each renal artery, unless this is not feasible for anatomical reasons.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Renal angiography alone
Description: Procedure will start with a local anesthesia of the femoral site to allow the placement of a 4-Fr sheath in the femoral artery, which allows a minimal risk of bleeding to the patient. Using JR-4 or similar diagnostic catheter, a selective renal angiography will be realized.
Study: NCT02713867

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study: NCT01028170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: furosemide and hypertonic saline solution
Description: 250-500 mg furosemide (30 min IV Q 12 hours) with 150 mL of 2.4% NaCl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: furosemide
Description: 80-160 mg furosemide (Given over 5 min IV twice a day)
Study: NCT04110470

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: X-ray
Description: Patients will receive standard radiographs post-operative day one or two in hospital, as well as radiographs in clinic at two and six weeks.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: No-Xray
Description: These patients will not have routine post-operative in hospital radiographs, or radiographs in clinic at two weeks, unless clinically indicated.
Study: NCT04180787

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beverage Consumption
Description: Participants will consume either VPX Bang® Keto Coffee beverage or flavor-matched placebo beverage in each condition.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Beverage Consumption
Description: Participants will consume either VPX Bang® Keto Coffee beverage or flavor-matched placebo beverage in each condition.
Study: NCT00628147

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Narrow band imaging colonoscope
Description: Adult colonoscopes with narrow band imaging capabilities (XCF-H160AY2L and XCF-Q160W6L, Olympus Medical Systems Corporation, Hachioji, Japan). There is an automatic switch on the handle of the endoscope that allows the physician to instantly switch between narrow band imaging and standard full spectrum white light modes.
Study: NCT01814670

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin Type A
Description: 20 units botulinum toxin Type A (total dose) injected into frown lines on Day 1.
Study: NCT03613935

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Product 2
Description: Comparison with products 1, 3, and 4
Study: NCT02412709

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QTScreen ECG Recorder
Description: Subjects will be randomly assigned to the: Parents Performing ECG (PPE) group or Staff Performing ECG (SPE) group. This will assess whether parents are able to use QTScreen on babies at home.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: QTScreen ECG Recorder
Description: Subjects will be randomly assigned to the: Parents Performing ECG (PPE) group or Staff Performing ECG (SPE) group. This will assess whether parents are able to use QTScreen on babies at home.
Study: NCT02636712

Intervention type: DEVICE
Intervention: ImageReady™ MR Conditional Pacing System
Study: NCT00877721

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self Mobility Improvement in the eLderly by using the SMILING system
Description: The effect of treatment with the SMILING system on postural stability and gait of elderly individuals will be measured using RCT cross over study design
Study: NCT05190055

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bone graft delivery system/wiltrom interbody fusion system/wiltrom spinal fixation system
Description: After receiving prophylactic antibiotics according to the local hospital protocol, the patients were generally anesthetized in a prone position. Paramedian or midline posterior sections were conducted, exposing the lumber vertebras encompassing the facet joints. The facet joints were removed, and decompression was performed. The diseased disc nucleus was then excised before filling in the bone substitutes. In the case of the device group, a novel filler tube with an integrated threaded rod, which can be connected to a surgical drill, A PEEK interbody fusion cage was then placed into the disc space followed by fixation with pedicle screws.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: wiltrom interbody fusion system/wiltrom spinal fixation system
Description: After receiving prophylactic antibiotics according to the local hospital protocol, the patients were generally anesthetized in a prone position. Paramedian or midline posterior sections were conducted, exposing the lumber vertebras encompassing the facet joints. The facet joints were removed, and decompression was performed. The diseased disc nucleus was then excised before filling in the bone substitutes. For the control group, the bone substitutes were filled in the disc space manually using a bone grafting funnel. A PEEK interbody fusion cage was then placed into the disc space followed by fixation with pedicle screws.
Study: NCT04418908

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetrorelix acetate, 0.25 mg/day
Description: All participants self-administered GnRHant daily between the baseline and follow-up visits (cetrorelix acetate, 0.25 mg/day).
Study: NCT01600053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be taken orally days 1-21 for up to six 28-day cycles (6 cycles = 1 course of Revlimid consolidation). Revlimid will be initiated at 5mg and can be dose escalated at the start of each cycle based on individual patient tolerability to a maximum of 25 mg. The total number of treatment cycles cannot exceed 12 cycles or two courses of six cycles each.